COMPANY PROFILE

Vaderis Therapeutics

Explore full profile

Oral AKT inhibitor engasertib for hereditary hemorrhagic telangiectasia

Basel, SwitzerlandFounded 2020Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Vaderis Therapeutics

Vaderis Therapeutics is a Basel clinical-stage biopharmaceutical company developing targeted therapies for rare vascular diseases, led by President and CEO Azmi Nabulsi. Its lead candidate engasertib (VAD044) is an investigational once-daily oral allosteric AKT1/2 inhibitor for hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disorder with no approved therapies worldwide. In August 2026 Vaderis closed an oversubscribed $152 million Series B co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital and existing investors Medicxi and Droia, and initiated the global Phase 3 HEROIC study. Capital is intended to fund operations through potential U.S. regulatory approval. Sources: PR Newswire 11 Aug 2026; Fierce Biotech.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Basel, Switzerland
Employees: 22
Open positions: None listed
Dealroom signal: 93.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based, Swiss DT Biotech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Aug 2026	$152M	$608M	Omega Funds · Perceptive Advisors · Medicxi · EQT Life Sciences	↗
LATE VC✓Equity / VC	Jan 2020	$17M	$66M	Medicxi	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Vaderis Therapeutics website traffic

Latest recorded traffic for Vaderis Therapeutics is 1.3K monthly website visits, down 59.4% over the last three months. Vaderis Therapeutics's team grew 37.5% over the past year.

Latest monthly visits1.3K 3-month web change-59.4% 1-year team growth+37.5%

Monthly website visitsJul 2022–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
APActelion PharmaceuticalsActelion Pharmaceuticals Ltd: We focus on the discovery, development, and commercialization of innovative treatments for diseases with high unmet medical needs.	Allschwil, Switzerland	Acquired	456	$12M	$30B
CTChord TherapeuticsDeveloping drugs for patients with rare, life-threatening, and severely disabling diseases	Geneva, Switzerland	Acquired
VEVectivBioClinical-stage biotechnology company focused on rare conditions with a well-defined biology that can be targeted with transformational therapeutics	Basel, Switzerland	Acquired
VPVicarius PharmaResearch-driven pharmaceutical, biotech and medical devices	Küssnacht (SZ), Switzerland	Closed
SESelexisSelexis develops cell lines for the biopharmaceutical industry	Geneva, Switzerland	Acquired
SOSompharmaceuticalsSomatostatin analogue therapy for rare diseases	Epalinges, Switzerland	Acquired
STSuzhou Huitherapy Biomedical Technology a high-tech enterprise engaged in the industrialization of comprehensively providing nucleic acid drugs	China	Operational
ATAlamab TherapeuticsClinical Trial Approval in Australia	Princeton, United States	Operational